Bestrophin 1 treatment trial on the effectiveness of Ravicti
This clinical trial is investigating whether an existing medicine called Ravicti can help treat inherited eye conditions known as bestrophinopathies, including Best disease (BVMD) and autosomal recessive bestrophinopathy (ARB). In these conditions, a faulty protein prevents cells at the back of the eye from working properly, leading to progressive vision loss. Ravicti is already approved for a different condition, but research suggests it may also help this faulty eye protein work better. In this study, run by Manchester University NHS Foundation Trust, participants aged 18 to 65 will take Ravicti for seven days and a dummy medicine (placebo) for seven days, with a break in between. Researchers will measure the eye's natural electrical signals to see if Ravicti improves cell activity. The trial aims to find out if repurposing this medicine could become a future treatment option for genetic eye conditions.
En un coup d'œil
De quoi parle cette étude ?
Bestrophinopathies are a group of rare, inherited eye conditions that cause gradual sight loss. They include conditions such as Best vitelliform macular dystrophy (BVMD) and autosomal recessive bestrophinopathy (ARB). In a healthy eye, a protein called bestrophin works like a tiny gatekeeper, helping essential minerals move in and out of cells in the retina at the back of the eye. When this protein is faulty, the cells cannot work properly, which gradually damages the light-sensing cells needed for clear vision.
Currently, there are very few treatments that address the root cause of these conditions. This study is testing a medicine called Ravicti. While Ravicti is already used safely within the NHS for an unrelated metabolic condition, laboratory research has shown that it might also help faulty bestrophin proteins work more effectively.
Researchers want to see if taking Ravicti can temporarily restore protein activity in patients. To measure this, doctors use a safe, routine test called an electrooculogram (EOG). This test checks the natural electrical responses in the eye, which show how well the bestrophin protein is performing. If the test results improve while taking Ravicti, it could prove that the medicine is helping the cells function again.
By testing a medicine that is already approved for human use, doctors hope to speed up the discovery of treatments that could one day slow down or prevent vision loss for people living with genetic eye diseases.
Points clés
- The trial tests whether the drug Ravicti can improve cell function in rare inherited eye conditions (bestrophinopathies).
- It is open to adults aged 18 to 65 with a confirmed diagnosis of BVMD (Best disease) or ARB.
- Participants take Ravicti for one week and a dummy medicine (placebo) for one week, with a three-week break in between.
- Non-invasive electrical eye tests (EOG) will measure whether the medicine helps eye cells work better.
- Taking part is voluntary, and you can withdraw at any point without affecting your routine NHS care.
Qui peut être éligible ?
You may be able to join this study if you are between 18 and 65 years old and have a confirmed genetic and clinical diagnosis of an inherited bestrophin eye condition (such as Best disease or ARB). You must have some remaining vision (better than only seeing hand movements) and be able to speak and understand English so you can follow the instructions and give informed consent.
You will not be able to take part if you are pregnant, planning a pregnancy, or breastfeeding. The trial is also not suitable for people with liver disease, serious gut absorption problems, or certain metabolic disorders (such as urea cycle disorders).
In addition, you cannot join if you have taken part in another clinical drug trial within the past 12 weeks, or if you take specific prescription medicines that could interact with Ravicti, including probenecid, certain strong sedatives, or particular immune-system drugs. The study team can review your current medications to see if they are safe to use during the trial.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- I am aged between 18 and 65 years old.
- I have a confirmed clinical and genetic diagnosis of Best disease (BVMD) or ARB.
- My eyesight is better than only being able to see hand movements.
- I am not pregnant, planning a pregnancy, or breastfeeding.
- I do not have liver disease or serious gut absorption problems.
- I have not taken part in another clinical drug trial in the last 12 weeks.
En quoi consiste la participation ?
Taking part involves taking the study medicine (Ravicti) by mouth for 7 days, followed by a 21-day rest period with no medication, and taking a dummy medicine (placebo) for 7 days. Because this is a 'crossover' trial, every participant tests both the real medicine and the placebo at different times, but neither you nor the doctors will know which one you are taking first.
You will need to visit the clinic at Manchester University NHS Foundation Trust for eye examinations and safety checks. These include standard eye tests that record electrical activity in the eye (EOG and ERG), a routine blood test to check your liver health, and a urine pregnancy test for women. A doctor is on call 24 hours a day if you feel unwell or have questions about taking the study drug.
Risques et avantages potentiels
Emplacements (1)
- St Mary's HospitalApproximatifManchester, England
Questions fréquentes
Will taking Ravicti cure my sight loss?
No, this trial is not a cure. It is an early-stage study designed to see if the medicine can temporarily help faulty eye cells work better. Taking part is unlikely to give you permanent vision improvement.
What is a placebo and why is it used?
A placebo looks just like the real medicine but contains no active ingredients. Comparing Ravicti against a placebo helps researchers know whether any changes in your eye tests are truly caused by the drug.
Does the electrooculogram (EOG) eye test hurt?
No. The EOG is a safe, painless test that uses small sticky sensors placed on the skin around your eyes to record natural electrical signals while you look at lights.
What happens if I experience side effects during the study?
You will be given a 24-hour phone number for the study medical team. If you feel unwell, a doctor can advise you and, if necessary, immediately find out which treatment you were taking to ensure you receive the right care.
Do I have to travel to Manchester to take part?
Yes, all study visits, health checks, and specialised eye tests are conducted at Manchester University NHS Foundation Trust.
Comment en savoir plus
Eva Lenassi
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.